why choose us

First received: October 06, 2022

Clinical Trial: Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Muscle Invasive Bladder Carcinoma

Study Type: INTERVENTIONAL


Official Title: A Pilot Single Arm Trial With Sacituzumab Govitecan as Neoadjuvant Therapy in Pts With Non-Urothelial Muscle Invasive Bladder Cancer

Brief Summary: This phase II trial tests whether sacituzumab govitecan given before radical cystectomy works in treating patients with non-urothelial bladder cancer.Sacituzumab govitecan contains a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan.Sacituzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as TROP2 receptors, and delivers govitecan to kill them.Giving sacituzumab govitecan before radical cystectomy…

Read more